Close

BIO Board of Directors

In accordance with its Bylaws and Articles of Incorporation, the Biotechnology Innovation Organization (BIO) is governed by its Board of Directors.  The Full BIO Board of Directors is comprised of all the directors sitting on the Section Governing Boards, as described below. 

In addition, there is a Board Executive Committee that consists of the seven Elected Officers of the Organization, the immediate Past Chair of the Organization, the Vice Chairs of each Section's Governing Board, and At-Large Directors selected from the Full Board.

There are four Section Governing Boards organized by industrial sector and policy interest.  They are: (1) the Emerging Companies Section (ECS) Governing Board, (2) the Food & Agriculture (F&A) Section Governing Board, (3) the Health Section Governing Board, and (4) the Industrial & Environmental (I&E) Section Governing Board.  BIO’s four Section Governing Boards are comprised of thought leaders who bring their expertise to bear on major issues affecting their specific area of the biotechnology industry.

From time to time, each Section Governing Board may consider candidates to fill vacancies in accordance with BIO’s Bylaws and their own processes and criteria.  In general, BIO Board candidates should be the CEO or Chairman of the Board of a research and development (R&D) focused biotechnology company, but certain Governing Boards have alternative criteria, especially for larger companies.  To be considered for a BIO Board seat, a candidate typically has this type of affiliation with a BIO member company.  If your organization is not a BIO member, click here to learn more about membership.

BECOME A BIO MEMBER

BIO is committed to fostering workforce development, diversity, and inclusion (WDDI) at BIO and across the biotechnology industry.  To that end, candidates should affirmatively support BIO’s WDDI Principles, and pledge to do her or his part to foster diversity and inclusion among employees, customers, and patients.  BIO’s WDDI Principles can be found at: https://www.bio.org/diversity

If you are interested in nominating yourself or another person to be a candidate and potentially fill a vacancy on the BIO Board, please inquire here to learn more about the BIO Board nomination process:

Inquire about BIO Board Nominations

If you have any questions about the BIO Board of Directors, please contact Peter McHugh at pmchugh@bio.org.

For reference, a diagram of the Board and Committee structure is presented below.

Board and Committee structure

 

Executive Committee

Executive Committee

  • John Maraganore, PhD Chair
    CEO, Alnylam Pharmaceuticals, Inc.
  • Katrine Bosley ECS Chair
    Chief Executive Officer, Editas Medicine
  • Philip W. Miller Food & Ag Section Chair
    Vice President, Global Corporate Affairs, Monsanto Company
  • Ronald L. Stotish Food & Ag Section Vice Chair
    Chief Executive Officer, Aqua Bounty Technologies, Inc
  • Alan Shaw, PhD I&E Section Chair
    President & CEO, Calysta
  • Vince Sewalt, PhD I&E Section Vice Chair
    Senior Director, Product Stewardship & Regulatory, Dupont Corporation
  • Jeremy M. Levin Health Section Vice Chair
    Chairman & CEO, Ovid Therapeutics Inc.
  • Ron Cohen, MD Immediate Past Chair
    CEO, Acorda Therapeutics, Inc
  • Bradford A. Zakes, MBA Treasurer
    Chief Executive Officer, Cerevast Therapeutics, Inc
  • Julie L. Gerberding, MD, MPH Secretary
    Executive Vice President, Communications, Global Policy, and Population Health &, Merck
  • Bill Anderson
    CEO & Head of North American Commercial Operations, Genentech, A Member of the Roche Group
  • Stuart A. Arbuckle
    Executive Vice President and Chief Commercial Office, Vertex Pharmaceuticals Incorporated
  • Douglas A. Doerfler
    President & CEO, MaxCyte, Inc
  • Paul J. Hastings
    President & CEO, Nkarta Inc.
  • Rachel K. King
    Founder & CEO, GlycoMimetics, Inc
  • Michael Narachi
    President and Chief Executive Officer, Orexigen Therapeutics, Inc
  • Joshua J. Ofman, MD
    Senior Vice President, Global Value, Access and Policy, Amgen Inc.
  • Richard Pops
    Chairman & CEO, Alkermes, Inc.
  • Christi L. Shaw
    SVP & President of Lilly Bio-Medicines, Eli Lilly and Company
  • Eddie J. Sullivan, PhD
    President & CEO, SAB Biotherapeutics
  • Section Governing Boards

    Emerging Companies Section Governing Board

  • Katrine Bosley ECS Chair
    Chief Executive Officer, Editas Medicine
  • Martin Babler
    Chief Executive Officer, Principia Biopharma
  • Laura A. Berezin
    Partner, Cooley LLP
  • Abbie Celniker, PhD
    Partner, Third Rock Ventures, LLC
  • Jeffrey L. Cleland, PhD
    President & CEO, Graybug Vision, Inc.
  • Ron Cohen, MD
    CEO, Acorda Therapeutics, Inc
  • John F. Crowley, JD, MBA
    Chairman & CEO, Amicus Therapeutics, Inc
  • Bassil I. Dahiyat, PhD
    President & CEO, Xencor, Inc
  • Douglas A. Doerfler
    President & CEO, MaxCyte, Inc
  • Mark Drozdowski
    Partner - Pharmaceuticals National Audit Leader, KPMG LLP
  • Maxine Gowen, PhD
    President & CEO, Trevena, Inc.
  • Paul J. Hastings
    President & CEO, Nkarta Inc.
  • Russell H. Herndon
    President & CEO, Hydra Biosciences, Inc
  • Jeff B. Kindler
    Chief Executive Officer, Centrexion Therapeutics
  • Rachel K. King
    Founder & CEO, GlycoMimetics, Inc
  • Scott Koenig, MD, PhD
    President & CEO, MacroGenics, Inc
  • Nick Leschly
    President & CEO, bluebird bio
  • Jeremy M. Levin
    Chairman & CEO, Ovid Therapeutics Inc.
  • Ted W. Love, MD
    Chief Executive Officer, Global Blood Therapeutics
  • Sandy Macrae, PhD
    President & CEO, Sangamo Therapeutics, Inc.
  • David Main
    CEO, Aquinox Pharmaceuticals, Inc.
  • John Maraganore, PhD
    CEO, Alnylam Pharmaceuticals, Inc.
  • Joel S. Marcus
    Chief Executive Officer, Alexandria Real Estate Equities, Inc
  • Jeffrey D. Marrazzo
    Co-Founder & CEO, Spark Therapeutics
  • Sharon Mates, PhD
    Chairman & CEO, Intra-Cellular Therapies, Inc.
  • Steven J. Mento, PhD
    President & CEO, Co-Founder, Conatus Pharmaceuticals, Inc
  • Kenneth I. Moch
    President & CEO, Cognition Therapeutics
  • Bob More
    President & CEO, Alta Partners
  • Lonnie Moulder
    Chief Executive Officer, Tesaro, Inc.
  • Michael Narachi
    President and Chief Executive Officer, Orexigen Therapeutics, Inc
  • Amir Nashat
    Managing Partner, Polaris Ventures
  • William J. Newell, JD
    Chief Executive Officer, Sutro Biopharma, Inc
  • Julia Owens, PhD
    Founder & CEO, Millendo Therapeutics Inc.
  • Carlos V. Paya, MD, PhD
    Chief Executive Officer, Immune Design Corporation
  • Adelene Q. Perkins
    CEO, Infinity Pharmaceuticals, Inc.
  • Anna Protopapas, MBA
    President & CEO, Mersana Therapeutics, Inc
  • Mark Pruzanski, MD
    Founder, President & CEO, Intercept Pharmaceuticals, Inc
  • Michael G. Raab
    Chief Executive Officer, Ardelyx Inc.
  • James Sapirstein, MBA, RPh
    Chief Executive Officer, Contravir Pharmaceuticals
  • George A. Scangos, PhD
    Chief Executive Officer, VIR Biotechnology, Inc.
  • Nancy Simonian, MD
    Chief Executive Officer, Syros Pharmaceuticals
  • Gil Van Bokkelen, PhD
    Chairman & CEO, Athersys, Inc
  • Timothy P. Walbert
    Chairman, President & CEO, Horizon Pharma, plc
  • Sue Washer, MBA
    President & CEO, Applied Genetic Technologies Corporation (AGTC)
  • Thomas G. Wiggans, MBA
    Founder & CEO, Dermira, Inc.
  • Robert J. Wills, PhD
    VP, Alliance Management - Business Development, Pharma Group, GTx, Inc
  • Bradford A. Zakes, MBA
    Chief Executive Officer, Cerevast Therapeutics, Inc
  • Food & Agriculture Section Governing Board

  • Philip W. Miller Chair
    Vice President, Global Corporate Affairs, Monsanto Company
  • Ronald L. Stotish Vice Chair
    Chief Executive Officer, Aqua Bounty Technologies, Inc
  • Jerry Flint
    Vice President, Global Initiatives and Sustainability, Corteva Agriscience, Ag Division of DowDuPont
  • Scott Holmstrom
    Senior Director, Global Product Development, Elanco
  • Sarah Hull
    Global Head Business Sustainability Seeds/Head Business Sustainability N.A., Syngenta
  • Tammy Lee
    President & CEO, Recombinetics, Inc
  • Dan Meagher
    President & CEO, Agrivida, Inc.
  • Adam Monroe
    President, Americas, Novozymes
  • Eddie J. Sullivan, PhD
    President & CEO, SAB Biotherapeutics
  • Karsten Temme, PhD
    CEO & Co-Founder, Pivot Bio, Inc.
  • Frank Terhorst
    Global Head of Seeds, Bayer CropScience, Inc.
  • Health Section Governing Board

  • John Maraganore, PhD Chair
    CEO, Alnylam Pharmaceuticals, Inc.
  • Ron Cohen, MD Immediate Past Chair
    CEO, Acorda Therapeutics, Inc
  • Michael Narachi Secretary
    President and Chief Executive Officer, Orexigen Therapeutics, Inc
  • Gregg H. Alton, Esq
    Executive Vice President, Corporate and Medical Affairs, Gilead Sciences, Inc
  • Bill Anderson
    CEO & Head of North American Commercial Operations, Genentech, A Member of the Roche Group
  • Stuart A. Arbuckle
    Executive Vice President and Chief Commercial Office, Vertex Pharmaceuticals Incorporated
  • Martin Babler
    Chief Executive Officer, Principia Biopharma
  • Jean-Jacques Bienaime
    President & CEO, BioMarin Pharmaceutical, Inc
  • Katrine Bosley
    Chief Executive Officer, Editas Medicine
  • Albert Bourla, PhD
    Chief Operating Officer, Pfizer Inc.
  • Carsten Brunn
    Head of Pharmaceuticals, Americas Region, Bayer Corporation
  • Bill Campbell
    Executive Vice President and Chief Commercial Officer, CSL Behring
  • Fabrice Chouraqui, PhD
    President, Novartis Pharmaceuticals Corporation
  • Terrie Curran
    President, Inflammation and Immunology, Celgene Corporation
  • Douglas A. Doerfler
    President & CEO, MaxCyte, Inc
  • Mark Enyedy
    President and Chief Executive Officer, ImmunoGen, Inc
  • William Fitzsimmons, MS, PharmD
    Divisional EVP for Global Regulatory Affairs & Global Clinical &Research Quality, Astellas Pharma Inc.
  • Barry Flannelly, PharmD
    Executive Vice President & General Manager US, Incyte Corporation
  • Scott Garland
    President, Relypsa, Inc
  • Julie L. Gerberding, MD, MPH
    Executive Vice President, Communications, Global Policy, and Population Health &, Merck
  • Maxine Gowen, PhD
    President & CEO, Trevena, Inc.
  • Paul J. Hastings
    President & CEO, Nkarta Inc.
  • Christopher P. Healey
    VP, Public Affairs, Grifols
  • Russell H. Herndon
    President & CEO, Hydra Biosciences, Inc
  • Rachel K. King
    Founder & CEO, GlycoMimetics, Inc
  • Scott Koenig, MD, PhD
    President & CEO, MacroGenics, Inc
  • Joseph LaRosa
    President & CEO, Regeneron Pharmaceuticals, Inc
  • John Lepore, MD
    SVP, R&D Pipeline, GlaxoSmithKline
  • Nick Leschly
    President & CEO, bluebird bio
  • Jeremy M. Levin
    Chairman & CEO, Ovid Therapeutics Inc.
  • Elizabeth Lewis
    Chief Counsel, Global Oncology Business Unit, Patient Advocacy, Takeda Oncology
  • Sabine Luik, MD, MPH
    Senior Vice President, Medicine and Regulatory Affairs, Boehringer Ingelheim
  • Kiran Mazumdar-Shaw
    Chairperson & Managing Director, Biocon Limited
  • Paul McKenzie, PhD
    EVP, Pharmaceutical Operations & Technology, Biogen
  • Clive A. Meanwell, MD, PhD
    Founder, Chairman & CEO, The Medicines Company
  • Steven J. Mento, PhD
    President & CEO, Co-Founder, Conatus Pharmaceuticals, Inc
  • Kenneth I. Moch
    President & CEO, Cognition Therapeutics
  • Michael M. Morrissey, PhD
    President & CEO, Exelixis, Inc
  • William J. Newell, JD
    Chief Executive Officer, Sutro Biopharma, Inc
  • C. David Nicholson, PhD
    Chief R&D Officer, Allergan PLC
  • Joshua J. Ofman, MD
    Senior Vice President, Global Value, Access and Policy, Amgen Inc.
  • Carlos V. Paya, MD, PhD
    Chief Executive Officer, Immune Design Corporation
  • Adelene Q. Perkins
    CEO, Infinity Pharmaceuticals, Inc.
  • Anne Phillips, MD
    SVP, Clinical, Medical & Regulatory Affairs, Novo Nordisk
  • Richard Pops
    Chairman & CEO, Alkermes, Inc.
  • Shaji Procida
    President & COO, Eisai, Inc
  • Howard W. Robin
    President & CEO, Nektar Therapeutics, Inc
  • Michael Ryan, PhD
    SVP for US Value, Access, Pricing and Health Economics and Outcomes Research, Bristol-Myers Squibb Company
  • James Sapirstein, MBA, RPh
    Chief Executive Officer, Contravir Pharmaceuticals
  • Christi L. Shaw
    SVP & President of Lilly Bio-Medicines, Eli Lilly and Company
  • Bill Sibold
    Executive Vice President, Sanofi Genzyme
  • Nancy Simonian, MD
    Chief Executive Officer, Syros Pharmaceuticals
  • Mark Skaletsky
    Chairman & CEO, Fenway Pharmaceuticals, Inc
  • David M. Stack
    President & CEO, Pacira Pharmaceuticals, Inc.
  • Perry Sternberg
    Head, US Commercial, Shire
  • James Sullivan, PhD
    Vice President, Pharmaceutical Discovery, AbbVie Inc.
  • Jennifer Taubert
    Company Group Chairman, Pharmaceuticals, The Americas, Johnson & Johnson
  • Helen Torley, MRCP
    President, Chief Executive Officer, Halozyme Therapeutics, Inc
  • Mark Trudeau
    President & CEO, Mallinckrodt Pharmaceuticals
  • Gil Van Bokkelen, PhD
    Chairman & CEO, Athersys, Inc
  • Charl Van Zyl
    Chief Operating Officer, UCB SA
  • Timothy P. Walbert
    Chairman, President & CEO, Horizon Pharma, plc
  • H. Thomas Watkins
    Chair Emeritus, BIO, Biotechnology Innovation Organization
  • Rick E. Winningham
    Chief Executive Officer, Theravance Biopharma US, Inc.
  • Gary Zieziula
    President & Managing Director, North America, EMD Serono, Inc
  • Industrial & Environmental Section Governing Board

  • Alan Shaw, PhD I&E Section Chair
    President & CEO, Calysta
  • Vince Sewalt, PhD I&E Section Vice Chair
    Senior Director, Product Stewardship & Regulatory, DuPont Industrial Biosciences
  • Doug Berven
    Vice President, Corporate Affairs, Poet, LLC
  • Patrick R. Gruber, MBA, PhD
    Chief Executive Officer, Gevo, Inc
  • Jennifer Holmgren, MBA, PhD
    Chief Executive Officer, LanzaTech
  • David Kettner
    Vice President of Legal Affairs, Virent, Inc
  • John G. Melo
    Chief Executive Officer, Amyris, Inc.
  • Christophe Schilling
    Chief Executive Officer, Genomatica, Inc
  • Chris Standlee
    Vice President, ICM, Inc
  • Brian Thome
    Chief Executive Officer, Edeniq Inc.
  • Simon Waddington, PhD
    Chief Executive Officer, Evolva
  • Robert F. Walsh
    Senior Vice President, Intrexon Corporation
  • Hugh C. Welsh, JD
    President, DSM North America
  • Roger Wyse, PhD
    Managing Director, Spruce Capital Partners
  • Jill Zullo
    Vice President, Bioindustrials NA, Cargill, Inc